Premium
A retrospective study of 152 women with vaginal intraepithelial neoplasia
Author(s) -
Zhang Jing,
Chang Xiaohan,
Qi Yafei,
Zhang Yao,
Zhang Shulan
Publication year - 2016
Publication title -
international journal of gynecology and obstetrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.895
H-Index - 97
eISSN - 1879-3479
pISSN - 0020-7292
DOI - 10.1016/j.ijgo.2015.08.014
Subject(s) - medicine , colposcopy , medical record , cervical intraepithelial neoplasia , dysplasia , retrospective cohort study , vagina , gynecology , vaginal cancer , hysterectomy , population , obstetrics , cervical cancer , surgery , cancer , environmental health
Objective To analyze the clinical characteristics and treatment of women with vaginal intraepithelial neoplasia (VAIN), as well as HPV prevalence in this population. Methods A retrospective review was undertaken of the medical records of women diagnosed with VAIN at a clinic in Shenyang, China, between January 1, 2009, and December 31, 2012. Results Of the 152 records reviewed, 69 (45.4%) women had low‐grade VAIN (VAIN1) and 83 (54.6%) had high‐grade VAIN (VAIN2/3). Among 110 patients with an available HPV status, 97 (88.2%) were positive. The predominant HPV types were HPV16, HPV33, HPV81, HPV53, HPV18, HPV58, and HPV66. Previous hysterectomy was documented in 60 (39.5%) patients. Additionally, 80 (52.6%) patients had no history of dysplasia of the lower genital tract. Of patients with VAIN1, 50 (72.5%) were treated by observation only, 31 (62.0%) of whom regressed spontaneously. Of 66 patients with VAIN2, 38 (57.6%) underwent treatment, 14 (36.8%) of whom experienced recurrence or progression. Of 17 patients with VAIN3, 13 (76.5%) underwent treatment, 5 (38.5%) of whom experienced recurrence or progression. Conclusion Evaluation of the entire vagina by colposcopy is warranted in each patient with abnormal cervical screening results. The predominant HPV genotypes among patients with VAIN could be used to establish diagnosis program and develop an HPV vaccine.